Category:Signatures
From BugSigDB
This category uses the form Signature.
Pages in category "Signatures"
The following 200 pages are in this category, out of 9,215 total.
(previous page) (next page)0–9
- 10.1038/s44220-023-00145-6/Experiment 1
- 10.3389/fevo.2022.742369/Experiment 1
- 10.3389/fevo.2022.742369/Experiment 1
- 10.3390/microorganisms13071456/Experiment 1
- 10.3390/microorganisms13071456/Experiment 1
- Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 1/Signature 1
- Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 2/Signature 1
- Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 2/Signature 2
- Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 3/Signature 1
- Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 4/Signature 1
- Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 4/Signature 2
- Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 5/Signature 1
- Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 5/Signature 2
- Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 6/Signature 1
- Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 6/Signature 2
- Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 7/Signature 1
- Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 7/Signature 2
- Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 8/Signature 1
- Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 8/Signature 2
- Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 9/Signature 1
- Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 9/Signature 2
- Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 10/Signature 1
- Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 10/Signature 2
- Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 11/Signature 1
- Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 11/Signature 2
- Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 12/Signature 1
- Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 12/Signature 2
- Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 13/Signature 1
- Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 13/Signature 2
- Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 14/Signature 1
- Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 14/Signature 2
- Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 15/Signature 1
- Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 15/Signature 2
- Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 16/Signature 1
- Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 16/Signature 2
- Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 17/Signature 1
- Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 17/Signature 2
- Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 18/Signature 1
- Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 18/Signature 2
- Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 19/Signature 1
- Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 19/Signature 2
- Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 20/Signature 1
- Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 20/Signature 2
- Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 21/Signature 1
- Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 21/Signature 2
- Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 22/Signature 1
- Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 23/Signature 1
- Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 24/Signature 1
- Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 25/Signature 1
- Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 25/Signature 2
- Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 26/Signature 1
- Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 26/Signature 2
- Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 27/Signature 1
- Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 27/Signature 2
- Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 28/Signature 1
- Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 28/Signature 2
- Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 29/Signature 1
- Toxic metals impact gut microbiota and metabolic risk in five African-origin populations/Experiment 29/Signature 2
- The intestinal microflora in allergic Estonian and Swedish 2-year-old children/Experiment 1/Signature 1
- The intestinal microflora in allergic Estonian and Swedish 2-year-old children/Experiment 1/Signature 2
- The intestinal microflora in allergic Estonian and Swedish 2-year-old children/Experiment 2/Signature 1
- The intestinal microflora in allergic Estonian and Swedish 2-year-old children/Experiment 2/Signature 2
- The salivary microbiota as a diagnostic indicator of oral cancer: a descriptive, non-randomized study of cancer-free and oral squamous cell carcinoma subjects/Experiment 1/Signature 1
- The salivary microbiota as a diagnostic indicator of oral cancer: a descriptive, non-randomized study of cancer-free and oral squamous cell carcinoma subjects/Experiment 1/Signature 2
- Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients/Experiment 1/Signature 2
- Quantitative differences in intestinal Faecalibacterium prausnitzii in obese Indian children/Experiment 1/Signature 1
- Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome/Experiment 1/Signature 1
- Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome/Experiment 1/Signature 2
- Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults/Experiment 1/Signature 1
- Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults/Experiment 1/Signature 2
- Pyrosequencing study of fecal microflora of autistic and control children/Experiment 1/Signature 1
- Pyrosequencing study of fecal microflora of autistic and control children/Experiment 1/Signature 2
- Toward defining the autoimmune microbiome for type 1 diabetes/Experiment 1/Signature 1
- Toward defining the autoimmune microbiome for type 1 diabetes/Experiment 1/Signature 2
- Toward defining the autoimmune microbiome for type 1 diabetes/Experiment 2/Signature 1
- Toward defining the autoimmune microbiome for type 1 diabetes/Experiment 2/Signature 2
- Toward defining the autoimmune microbiome for type 1 diabetes/Experiment 3/Signature 1
- Toward defining the autoimmune microbiome for type 1 diabetes/Experiment 3/Signature 2
- Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa/Experiment 1/Signature 1
- Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa/Experiment 1/Signature 2
- Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa/Experiment 2/Signature 1
- Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa/Experiment 3/Signature 1
- Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa/Experiment 3/Signature 2
- Effect of mother's weight on infant's microbiota acquisition, composition, and activity during early infancy: a prospective follow-up study initiated in early pregnancy/Experiment 1/Signature 1
- Effect of mother's weight on infant's microbiota acquisition, composition, and activity during early infancy: a prospective follow-up study initiated in early pregnancy/Experiment 2/Signature 1
- Effect of mother's weight on infant's microbiota acquisition, composition, and activity during early infancy: a prospective follow-up study initiated in early pregnancy/Experiment 3/Signature 1
- Effect of mother's weight on infant's microbiota acquisition, composition, and activity during early infancy: a prospective follow-up study initiated in early pregnancy/Experiment 4/Signature 1
- Disordered microbial communities in the upper respiratory tract of cigarette smokers/Experiment 1/Signature 1
- Disordered microbial communities in the upper respiratory tract of cigarette smokers/Experiment 1/Signature 2
- Disordered microbial communities in the upper respiratory tract of cigarette smokers/Experiment 2/Signature 1
- Disordered microbial communities in the upper respiratory tract of cigarette smokers/Experiment 2/Signature 2
- Disordered microbial communities in the upper respiratory tract of cigarette smokers/Experiment 3/Signature 1
- Disordered microbial communities in the upper respiratory tract of cigarette smokers/Experiment 3/Signature 2
- Disordered microbial communities in the upper respiratory tract of cigarette smokers/Experiment 4/Signature 1
- Disordered microbial communities in the upper respiratory tract of cigarette smokers/Experiment 4/Signature 2
- Molecular analysis of the luminal- and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome/Experiment 1/Signature 1
- Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome/Experiment 1/Signature 1
- Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome/Experiment 1/Signature 2
- Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome/Experiment 1/Signature 1
- Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome/Experiment 1/Signature 2
- Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome/Experiment 2/Signature 1
- Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome/Experiment 2/Signature 2
- Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome/Experiment 3/Signature 1
- Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome/Experiment 3/Signature 2
- Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome/Experiment 4/Signature 1
- Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome/Experiment 4/Signature 2
- Obesity-associated gut microbiota is enriched in Lactobacillus reuteri and depleted in Bifidobacterium animalis and Methanobrevibacter smithii/Experiment 1/Signature 1
- Obesity-associated gut microbiota is enriched in Lactobacillus reuteri and depleted in Bifidobacterium animalis and Methanobrevibacter smithii/Experiment 1/Signature 2
- Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers/Experiment 1/Signature 1
- Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers/Experiment 1/Signature 2
- Linking long-term dietary patterns with gut microbial enterotypes/Experiment 1/Signature 1
- Linking long-term dietary patterns with gut microbial enterotypes/Experiment 1/Signature 2
- Linking long-term dietary patterns with gut microbial enterotypes/Experiment 2/Signature 1
- Linking long-term dietary patterns with gut microbial enterotypes/Experiment 2/Signature 2
- Dynamic gut microbiome across life history of the malaria mosquito Anopheles gambiae in Kenya/Experiment 1/Signature 1
- Dynamic gut microbiome across life history of the malaria mosquito Anopheles gambiae in Kenya/Experiment 1/Signature 2
- Dynamic gut microbiome across life history of the malaria mosquito Anopheles gambiae in Kenya/Experiment 2/Signature 1
- Dynamic gut microbiome across life history of the malaria mosquito Anopheles gambiae in Kenya/Experiment 2/Signature 2
- Genomic analysis identifies association of Fusobacterium with colorectal carcinoma/Experiment 1/Signature 1
- Genomic analysis identifies association of Fusobacterium with colorectal carcinoma/Experiment 1/Signature 2
- Genomic analysis identifies association of Fusobacterium with colorectal carcinoma/Experiment 2/Signature 1
- Genomic analysis identifies association of Fusobacterium with colorectal carcinoma/Experiment 2/Signature 2
- Low diversity of the gut microbiota in infants with atopic eczema/Experiment 1/Signature 1
- Low diversity of the gut microbiota in infants with atopic eczema/Experiment 1/Signature 2
- Low diversity of the gut microbiota in infants with atopic eczema/Experiment 2/Signature 1
- Alterations in the gut microbiome of children with severe ulcerative colitis/Experiment 1/Signature 1
- Distinct gut microbiota in southeastern African and northern European infants/Experiment 1/Signature 1
- Distinct gut microbiota in southeastern African and northern European infants/Experiment 1/Signature 2
- Functional dysbiosis within the gut microbiota of patients with constipated-irritable bowel syndrome/Experiment 1/Signature 1
- Functional dysbiosis within the gut microbiota of patients with constipated-irritable bowel syndrome/Experiment 1/Signature 2
- Functional dysbiosis within the gut microbiota of patients with constipated-irritable bowel syndrome/Experiment 1/Signature 3
- Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome/Experiment 1/Signature 1
- Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome/Experiment 1/Signature 2
- Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome/Experiment 2/Signature 1
- Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome/Experiment 1/Signature 1
- Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome/Experiment 1/Signature 2
- The microbiota of the gut in preschool children with normal and excessive body weight/Experiment 1/Signature 1
- The microbiota of the gut in preschool children with normal and excessive body weight/Experiment 1/Signature 2
- Periodontal disease and the oral microbiota in new-onset rheumatoid arthritis/Experiment 1/Signature 1
- Periodontal disease and the oral microbiota in new-onset rheumatoid arthritis/Experiment 1/Signature 2
- Periodontal disease and the oral microbiota in new-onset rheumatoid arthritis/Experiment 2/Signature 1
- Periodontal disease and the oral microbiota in new-onset rheumatoid arthritis/Experiment 2/Signature 2
- Periodontal disease and the oral microbiota in new-onset rheumatoid arthritis/Experiment 3/Signature 1
- Periodontal disease and the oral microbiota in new-onset rheumatoid arthritis/Experiment 3/Signature 2
- Increased rectal microbial richness is associated with the presence of colorectal adenomas in humans/Experiment 1/Signature 1
- IBS-associated phylogenetic unbalances of the intestinal microbiota are not reverted by probiotic supplementation/Experiment 1/Signature 1
- IBS-associated phylogenetic unbalances of the intestinal microbiota are not reverted by probiotic supplementation/Experiment 1/Signature 2
- IBS-associated phylogenetic unbalances of the intestinal microbiota are not reverted by probiotic supplementation/Experiment 2/Signature 1
- IBS-associated phylogenetic unbalances of the intestinal microbiota are not reverted by probiotic supplementation/Experiment 2/Signature 2
- IBS-associated phylogenetic unbalances of the intestinal microbiota are not reverted by probiotic supplementation/Experiment 3/Signature 1
- IBS-associated phylogenetic unbalances of the intestinal microbiota are not reverted by probiotic supplementation/Experiment 3/Signature 2
- IBS-associated phylogenetic unbalances of the intestinal microbiota are not reverted by probiotic supplementation/Experiment 4/Signature 1
- Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome/Experiment 1/Signature 1
- Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome/Experiment 3/Signature 1
- Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome/Experiment 4/Signature 1
- Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer/Experiment 1/Signature 1
- Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer/Experiment 1/Signature 2
- Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer/Experiment 2/Signature 1
- Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer/Experiment 2/Signature 2
- Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer/Experiment 3/Signature 1
- Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer/Experiment 4/Signature 1
- Subgingival biodiversity in subjects with uncontrolled type-2 diabetes and chronic periodontitis/Experiment 1/Signature 1
- Subgingival biodiversity in subjects with uncontrolled type-2 diabetes and chronic periodontitis/Experiment 1/Signature 2
- High-throughput sequencing reveals the incomplete, short-term recovery of infant gut microbiota following parenteral antibiotic treatment with ampicillin and gentamicin/Experiment 1/Signature 1
- High-throughput sequencing reveals the incomplete, short-term recovery of infant gut microbiota following parenteral antibiotic treatment with ampicillin and gentamicin/Experiment 1/Signature 2
- High-throughput sequencing reveals the incomplete, short-term recovery of infant gut microbiota following parenteral antibiotic treatment with ampicillin and gentamicin/Experiment 2/Signature 1
- High-throughput sequencing reveals the incomplete, short-term recovery of infant gut microbiota following parenteral antibiotic treatment with ampicillin and gentamicin/Experiment 3/Signature 1
- High-throughput sequencing reveals the incomplete, short-term recovery of infant gut microbiota following parenteral antibiotic treatment with ampicillin and gentamicin/Experiment 3/Signature 2
- Alterations in intestinal microbiota of elderly Irish subjects post-antibiotic therapy/Experiment 1/Signature 1
- Alterations in intestinal microbiota of elderly Irish subjects post-antibiotic therapy/Experiment 1/Signature 2
- Alterations in intestinal microbiota of elderly Irish subjects post-antibiotic therapy/Experiment 2/Signature 1
- Alterations in intestinal microbiota of elderly Irish subjects post-antibiotic therapy/Experiment 2/Signature 2
- Alterations in intestinal microbiota of elderly Irish subjects post-antibiotic therapy/Experiment 3/Signature 1
- Alterations in intestinal microbiota of elderly Irish subjects post-antibiotic therapy/Experiment 3/Signature 2
- Alterations in intestinal microbiota of elderly Irish subjects post-antibiotic therapy/Experiment 4/Signature 1
- Metagenomic sequencing of the human gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes: correlation with inflammatory and metabolic parameters/Experiment 1/Signature 1
- Metagenomic sequencing of the human gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes: correlation with inflammatory and metabolic parameters/Experiment 1/Signature 2
- Gut microbiome composition is linked to whole grain-induced immunological improvements/Experiment 1/Signature 1
- Gut microbiome composition is linked to whole grain-induced immunological improvements/Experiment 1/Signature 2
- Gut microbiome composition is linked to whole grain-induced immunological improvements/Experiment 2/Signature 1
- Gut microbiome composition is linked to whole grain-induced immunological improvements/Experiment 2/Signature 2
- Gut microbiome composition is linked to whole grain-induced immunological improvements/Experiment 3/Signature 1
- Gut microbiome composition is linked to whole grain-induced immunological improvements/Experiment 3/Signature 2
- Gut microbiota composition is correlated to grid floor induced stress and behavior in the BALB/c mouse/Experiment 1/Signature 1
- The lung microbiome in moderate and severe chronic obstructive pulmonary disease/Experiment 1/Signature 1
- The lung microbiome in moderate and severe chronic obstructive pulmonary disease/Experiment 1/Signature 2
- The lung microbiome in moderate and severe chronic obstructive pulmonary disease/Experiment 2/Signature 1
- Microbiome dynamics of human epidermis following skin barrier disruption/Experiment 1/Signature 1
- Microbiome dynamics of human epidermis following skin barrier disruption/Experiment 1/Signature 2
- Modulation of potential respiratory pathogens by pH1N1 viral infection/Experiment 1/Signature 1
- Modulation of potential respiratory pathogens by pH1N1 viral infection/Experiment 1/Signature 2
- Modulation of potential respiratory pathogens by pH1N1 viral infection/Experiment 1/Signature 3
- Modulation of potential respiratory pathogens by pH1N1 viral infection/Experiment 1/Signature 4
- Modulation of potential respiratory pathogens by pH1N1 viral infection/Experiment 1/Signature 5
- Modulation of potential respiratory pathogens by pH1N1 viral infection/Experiment 1/Signature 6
- Fecal microbiota composition differs between children with β-cell autoimmunity and those without/Experiment 1/Signature 1
- Fecal microbiota composition differs between children with β-cell autoimmunity and those without/Experiment 1/Signature 2
- Fusobacterium is associated with colorectal adenomas/Experiment 1/Signature 1
- Microarray analysis reveals marked intestinal microbiota aberrancy in infants having eczema compared to healthy children in at-risk for atopic disease/Experiment 1/Signature 1
- Microarray analysis reveals marked intestinal microbiota aberrancy in infants having eczema compared to healthy children in at-risk for atopic disease/Experiment 1/Signature 2